Co-Authors
This is a "connection" page, showing publications co-authored by Walter Ambrosius and Nicholas Pajewski.
Connection Strength
1.213
-
Ambrosius WT, Polonsky TS, Greenland P, Goff DC, Perdue LH, Fortmann SP, Margolis KL, Pajewski NM. Design of the value of imaging in enhancing the wellness of your heart (VIEW) trial and the impact of uncertainty on power. Clin Trials. 2012 Apr; 9(2):232-46.
Score: 0.413
-
Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2021 05 20; 384(20):1921-1930.
Score: 0.392
-
Speiser JL, Ambrosius WT, Pajewski NM. Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials. Clin Trials. 2023 May 26; 17407745231177046.
Score: 0.225
-
Joseph J, Pajewski NM, Dolor RJ, Sellers MA, Perdue LH, Peeples SR, Henrie AM, Woolard N, Jones WS, Benziger CP, Orkaby AR, Mixon AS, VanWormer JJ, Shapiro MD, Kistler CE, Polonsky TS, Chatterjee R, Chamberlain AM, Forman DE, Knowlton KU, Gill TM, Newby LK, Hammill BG, Cicek MS, Williams NA, Decker JE, Ou J, Rubinstein J, Choudhary G, Gazmuri RJ, Schmader KE, Roumie CL, Vaughan CP, Effron MB, Cooper-DeHoff RM, Supiano MA, Shah RC, Whittle JC, Hernandez AF, Ambrosius WT, Williamson JD, Alexander KP. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. J Am Geriatr Soc. 2023 Jun; 71(6):1701-1713.
Score: 0.056
-
Wright JT, Whelton PK, Johnson KC, Snyder JK, Reboussin DM, Cushman WC, Williamson JD, Pajewski NM, Cheung AK, Lewis CE, Oparil S, Rocco MV, Beddhu S, Fine LJ, Cutler JA, Ambrosius WT, Rahman M, Still CH, Chen Z, Tatsuoka C. SPRINT Revisited: Updated Results and Implications. Hypertension. 2021 Dec; 78(6):1701-1710.
Score: 0.051
-
Potok OA, Ix JH, Shlipak MG, Katz R, Hawfield AT, Rocco MV, Ambrosius WT, Cho ME, Pajewski NM, Rastogi A, Rifkin DE. The Difference Between Cystatin C- and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis. 2020 12; 76(6):765-774.
Score: 0.046
-
Mottl AK, Pajewski N, Fonseca V, Ismail-Beigi F, Chew E, Ambrosius WT, Greven C, Schubart U, Buse J. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. J Diabetes Complications. 2014 Nov-Dec; 28(6):874-9.
Score: 0.030